May 15, 2017
Scrip
By Lucie Ellis
What caused Novartis’s innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto’s journey and what this experience shows about the changing face of pharma’s customers.